Video: FDA Approves Hologic's Adiana(R) Permanent Contracept...(lar diagnostic products including HPV an...),Health

Forward Looking Statement Disclaimer

This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the effect and adoption of the use of the Adiana system. There can be no assurance that the system will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the Adiana system can only be determined on a case-by-case basis depending on the particular circumstances of the procedure and patient in question. Thus there can be no assurance of general adoption of this technology by the medical community. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.

Hologic and Adiana are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

    Contact:  For Investors:          For Media:
              Deborah R. Gordon       Stephanie Cilibrasi
              Vice President,         Associate Product Manager, Adiana
              Investor Relations      Hologic, Inc.
              Hologic, Inc.           (508) 263-8974
              (781) 999-7716          adianamedia@hologic.com